DEM301 in advanced colorectal cancer: a first-in-human test

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

DEM301 is an investigational antibody-drug conjugate studied in a multicenter, open-label Phase 1 trial with two parts: dose escalation to find safe dose levels and dose expansion to further evaluate activity at selected doses. The study collects data on safety, pharmacokinetics, immunogenicity, pharmacodynamics, and exploratory biomarkers, along with preliminary antitumor activity. Approximately 60 participants who have progressed after prior therapies will be enrolled. Participants will undergo tumor biopsies in designated cohorts when feasible. Primary locations include sites in Australia.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥18 years.
2. Participants must have documented advanced (metastatic or unresectable) colorectal cancer that has progressed on or after prior standard-of-care treatment and must have received, or been unable to receive, applicable standard therapies as defined in the protocol.
3. Life expectancy ≥12 weeks.
4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
5. Have at least 1 measurable lesion at baseline suitable for repeat imaging evaluation by RECIST v1.1.
6. Adequate bone marrow, liver, kidney, and coagulation function per protocol requirements.
7. Agree to provide adequate tumor tissue for protocol-required biomarker assessment. Participants in designated cohorts must be willing to provide fresh tumor biopsies, unless medically contraindicated.
8. Female participants must not be pregnant or breastfeeding. Male and female participants must comply with protocol-defined reproductive and contraception requirements.
9. Have suitable venous access for study treatment and required blood sampling.
10. Be willing and able to comply with study assessments, schedule, and restrictions.
11. Written informed consent must be obtained before any study-related procedures are performed.

Exclusion Criteria:

1. Prior treatment with certain antibody-drug conjugates, as defined in the protocol. Protocol-defined exceptions may apply.
2. Recent anticancer therapy, investigational treatment, major surgery, or radiation therapy within the protocol-defined washout periods.
3. Ongoing clinically significant toxicity from prior therapy that has not recovered to the protocol-required level.
4. Active central nervous system (CNS) metastases or suspected or confirmed leptomeningeal disease. Participants with treated and stable brain metastases may be eligible.
5. Recent thromboembolic event or clinically significant cardiovascular disease.
6. Active or uncontrolled infection, including active viral hepatitis, unless protocol-defined eligibility criteria are met.
7. Known HIV infection or AIDS-related illness unless protocol-defined eligibility criteria are met.
8. History of or current drug-induced interstitial lung disease/pneumonitis, suspected interstitial lung disease (ILD)/pneumonitis, or other severe or uncontrolled chronic pulmonary disease.
9. Another malignancy within the previous 3 years, except certain malignancies with a low risk of recurrence.
10. Recent systemic corticosteroid therapy or live attenuated vaccination, except as permitted by the protocol.
11. Known hypersensitivity to DEM301 or its ingredients, or any serious medical, psychiatric, or other condition that, in the Investigator's opinion, could affect participant safety, study participation, or interpretation of study results.

Where it's running

• Clinical Site 104
  Birtinya, Queensland, Australia Recruiting
• Clinical Site 101
  Nedlands, Western Australia, Australia Recruiting

Study contacts

• Study coordinator: DEM301 Study Team
• Email: clinicaltrials@dembiopharma.com
• Phone: 857-242-1002

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Quality of life after colorectal cancer treatment

  This project will test whether late side effects at 6, 12, and 24 months affect quality of life in people aged 25–65 who completed initial treatment for colorectal cancer at the Institute of Oncology Ljubljana.

  Recruiting Institute of Oncology Ljubljana · Ljubljana · NCT07427901

• CEA-targeted CAR-T for advanced CEA-positive solid tumors

  This trial will try CEA-targeted CAR-T cell infusions in adults with advanced CEA-positive cancers (such as colorectal, gastric, esophageal, lung, or pancreatic cancer) to see if the treatment is safe and helps control the disease.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Hefei, Anhui · NCT07179692

• Preserving the superior left colic artery to improve blood flow to the descending colon before reconnecting the bowel after left-sided, rectal, or ovarian cancer surgery

  This trial will test in adults having left colon, rectal, or ovarian cancer surgery whether preserving the superior left colic artery and temporarily managing the inferior mesenteric artery improves blood flow to the descending colon and reduces healing problems after the bowel is reconnected.

  Recruiting Institut du Cancer de Montpellier - Val d'Aurelle · Montpellier, Herault · NCT07098182

• Virtual exercise program to preserve function and prevent disability during chemotherapy

  This trial tests whether supervised resistance sessions by video plus short home aerobic workouts help adults 18–64 maintain strength and stay active while receiving curative-intent chemotherapy.

  Recruiting at 29 sites Alliance for Clinical Trials in Oncology · Dublin, California and 29 other locations · NCT07059884

• Fruquintinib plus FOLFIRI for second-line metastatic colorectal cancer

  This study will test whether adding fruquintinib to FOLFIRI helps people with metastatic colorectal cancer who progressed after first-line FOLFOX plus bevacizumab.

  Recruiting at 14 sites Phase 2 SCRI Development Innovations, LLC · Denver, Colorado and 13 other locations · NCT07011576

• Evaluating a new CAR T-cell therapy for solid tumors expressing EGFR

  This study is testing a new CAR T-cell therapy to see if it can safely help adults with certain solid tumors, like colorectal and lung cancer, that have specific markers.

  Recruiting at 10 sites Phase 1/2 A2 Biotherapeutics Inc. · Gilbert, Arizona and 9 other locations · NCT06682793

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.